Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$19.51 USD
-32.19 (-62.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.08 +0.57 (2.92%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Corbus Pharmaceuticals Holdings, Inc. [CRBP]
Reports for Purchase
Showing records 1 - 20 ( 65 total )
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Q2 Financials; CRB-701 Ph 1 on Track to Complete in Q4:24.
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
CRB-701 Data in 1Q25, With Obesity (CRB-913) Start in 1Q25 Drive Pipeline Momentum
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Mind, Body, Cannabinoids; Initiating at OUTPERFORM
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Shrinking Tumors and Waistlines by Improving Nectin-4 and CB1 Targeting; Resuming Coverage With a Buy Rating and $80 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
An Early-Stage Pipeline with Compelling Scientific Rationale; Reit. Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Can It Compete? Corbus Expands Its Oncology Footprint With CRB-701, a Nectin-4 Targeting ADC
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Corbus Presenting Preclinical Data For CRB-601 During SITC ?22; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Integrin aab8 has Promising Potential in Tumor immunotherapy and Remains a Key Long-term Driver; Reit. Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Considerations on CRB-601 in Early I/O Pipeline Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
I/O Pipeline Pivot, Creates Questions Before Value; Reit. Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Turning Page to Integrin Development, Strategic Opportunities; SLE Top-line Expected 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Focusing on Lenabasum Clarity and Evolving Pipeline Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Lenabasum Setback In DM; Focusing Attention on Next Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A